North Carolina Headlines

DelveInsight’s “Schizophrenia Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of Schizophrenia, historical and forecasted epidemiology, as well as the Schizophrenia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Interested to know which emerging Schizophrenia therapies will capture the highest market share?

Download the report to understand the latest Schizophrenia market trends and forecasts- Schizophrenia Treatment Market – https://www.delveinsight.com/report-store/schizophrenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from the Schizophrenia Market Report

• The market size of Schizophrenia in the 7MM was more than USD 8 billion in 2025, which is further expected to increase by 2036.

• The Schizophrenia competitive landscape is undergoing dynamic changes with the approval of generic versions for drugs like LATUDA (lurasidone hydrochloride) and REXULTI, leading to a substantial decline in market revenue for these therapies during the forecasted years.

• BMS’s novel medication COBENFY (KarXT) received FDA approval on 26 September 2024, marking the first new treatment class for schizophrenia since the FDA approved CLOZARIL (clozapine) 35 years ago.

• As per DelveInsight’s analysis, in 2025 the total diagnosed prevalent cases of schizophrenia in the 7MM were nearly 4 million, of which the US accounted for nearly 1.5 million cases.

• Among the 7MM in 2025, EU4 and the UK together accounted for nearly 42% of the total diagnosed prevalent cases of schizophrenia.

• Second-generation antipsychotics (SGAs) continue to dominate the treatment landscape, favored over first-generation antipsychotics (FGAs) due to a lower propensity for serious side effects.

• Emerging therapies such as Ulotaront (SEP-363856), Brilaroxazine (RP5063), Roluperidone (MIN-101), Valbenazine (NBI-98854), LYN-005, and Evenamide (NW-3509) are projected to enter the market during the forecast period.

• The US accounted for the largest schizophrenia market size among the 7MM in 2025, at nearly USD 6 billion, followed by Japan at nearly USD 600 million.

• Germany led the EU4 and UK schizophrenia market in 2025 with an estimated size of approximately USD 460 million; however, the UK is projected to surpass Germany and become the largest market in the region by 2036.

Gain a competitive edge in the Schizophrenia Market by exploring our in-depth analysis @ Schizophrenia Treatment Market – https://www.delveinsight.com/report-store/schizophrenia-market

Schizophrenia Market Overview

The global Schizophrenia market is expected to strengthen as awareness of the disease increases and more effective interventions are developed. Schizophrenia is a complex, long-term, and severe mental disorder characterized by abnormalities in perception, thinking, emotions, and behavior, with onset typically occurring in late teens to early 20s for men and late 20s to early 30s for women.

At present, there is no cure for schizophrenia, and treatment primarily focuses on managing symptoms and preventing relapses through a combination of antipsychotic medication, psychosocial therapy, cognitive behavioral therapy, and, in some cases, electroconvulsive therapy (ECT) or hospitalization. Non-adherence remains a critical issue among patients, and while established atypical antipsychotics manage positive symptoms, their efficacy varies and they have limited impact on cognitive and negative symptoms, driving continued research into new therapeutic classes.

Factors Driving the Growth of the Schizophrenia MarketRising Schizophrenia Burden

Schizophrenia continues to impose a significant public health challenge, with prevalence projected to rise in the coming decade due to rising awareness regarding mental illness and improvements in diagnosis. Diagnosed prevalent cases in the 7MM are expected to grow further by 2036, driven by advancements in psychiatric research and evolving diagnostic criteria that enable more precise identification and earlier diagnosis of schizophrenia globally.

Evolving Treatment Landscape

Second-generation antipsychotics dominate the treatment market, aiming to address both positive and negative symptoms as well as neurocognitive impairments. Recent research indicates that long-acting injectables (LAIs) may be more effective than oral medications in reducing the risk of hospitalization, supporting growing adoption of injectable formulations such as ARISTADA/ARISTADA INITIO, ABILIFY MAINTENA, the INVEGA products, and UZEDY.

Approval of Novel Therapeutic Classes

BMS’s KarXT – now named COBENFY – received FDA approval on 26 September 2024 for the treatment of adults with schizophrenia. COBENFY is the first muscarinic agonist approved for schizophrenia, marking the first new treatment class for the condition since CLOZARIL (clozapine) was approved 35 years earlier.

Launch of Emerging Schizophrenia Drugs

The competitive landscape is set to expand further with several promising emerging therapies projected to launch during the forecast period, including Teva/MedinCell/Royalty Pharma’s Olanzapine LAI (TEV-‘749), Sumitomo Pharma/Otsuka’s Ulotaront (SEP-363856), Reviva Pharmaceuticals’ Brilaroxazine (RP5063), Minerva Neurosciences/Mitsubishi Tanabe’s Roluperidone (MIN-101), Neurocrine/Mitsubishi Tanabe’s Valbenazine (NBI-98854), Lyndra Therapeutics’ LYN-005, and Newron Pharmaceuticals’ Evenamide (NW-3509).

Schizophrenia Market Segment Analysis

Among the 7MM, current market segmentation is based on the therapies prescribed, with drugs such as CAPLYTA (lumateperone), VRAYLAR (US)/REAGILA (EU) (cariprazine), LATUDA (lurasidone), and REXULTI (US/JP)/RXULTI (EU) forming major segments of the forecast model. On the epidemiology side, among EU4 and the UK in 2025, diagnosed prevalent cases of schizophrenia by severity accounted for approximately 380,000 mild, 600,000 moderate, and 640,000 severe cases.

Schizophrenia Market Regional AnalysisThe US is Expected to Dominate the Overall Schizophrenia Market

Among the 7MM in 2025, the US accounted for the largest market size of schizophrenia at nearly USD 6 billion, compared to EU4 (Germany, France, Italy, and Spain), the UK, and Japan. The US also accounted for nearly 1.5 million of the roughly 4 million total diagnosed prevalent cases of schizophrenia across the 7MM in 2025, with diagnosed prevalence at approximately 780,000 for males and 670,000 for females.

Among EU4 and the UK, Germany led the schizophrenia market in 2025 with an estimated size of approximately USD 460 million; however, by 2036, the UK is projected to surpass Germany to become the largest market in the region. The market size of schizophrenia in Japan was valued at nearly USD 600 million in 2025, capturing the second-highest market size, which is expected to increase by 2036 as novel emerging therapies enter the market.

Schizophrenia Key Companies

Schizophrenia Companies include:

• Boehringer Ingelheim

• Sumitomo Pharma

• Otsuka Pharmaceuticals

• Reviva Pharmaceuticals

• Minerva Neurosciences

• Mitsubishi Tanabe Pharma

• Karuna Therapeutics

• Bristol Myers Squibb

• Royalty Pharma

• Acadia Pharmaceuticals

• Rovi Pharmaceuticals Laboratories (Laboratorios Farmacéuticos Rovi)

• Teva Pharmaceutical

• MedinCell

• Lyndra Therapeutics

• Neurocrine Biosciences

• Luye Pharma

• Newron Pharmaceuticals

• And Others.

Download the report to understand which factors are driving Schizophrenia Market Trends- Schizophrenia Treatment Market

Latest Highlights from the Schizophrenia Market

• In February 2026, the US FDA accepted Teva Pharmaceutical Industries’ New Drug Application (NDA) for its investigational drug, olanzapine extended-release injectable suspension (TEV-‘749), intended for once-monthly treatment of schizophrenia in adults.

• In January 2026, Reviva announced publication of clinical vocal biomarker data from the RECOVER Phase III clinical trial of brilaroxazine to treat negative symptoms in schizophrenia.

• In December 2025, the FDA recommended that Reviva conduct a second Phase III clinical trial of brilaroxazine in patients with schizophrenia to generate additional efficacy data and expand the safety database, with the RECOVER-2 Phase III trial planned to begin in the first half of 2026.

• In December 2025, Teva filed an FDA NDA for its once-monthly olanzapine extended-release injectable, supported by Phase III SOLARIS data demonstrating sustained efficacy, safety, tolerability, and potential adherence benefits.

• The Phase III RECOVER-2 trial of brilaroxazine in schizophrenia is expected to begin in mid-2025, pending additional financing, with topline results anticipated in Q3 2026 and potential NDA submission in Q4 2026.

Discover key developments and opportunities in the Schizophrenia Market @ Schizophrenia Treatment Market

Schizophrenia Market Outlook

Schizophrenia is a severe and chronic mental disorder characterized by distorted thinking, perception, emotions, language, sense of self, and behavior, with impacts extending beyond patients to family members, caregivers, and society due to its lifelong nature and likelihood of relapses. The disorder progresses through prodromal, active, and residual stages, each marked by specific symptoms such as hallucinations, suspiciousness, delusions, depression, withdrawal, anxiety, and difficulty concentrating.

The Schizophrenia market remains replete with antipsychotic drugs utilizing diverse routes of administration, with a primary focus on dopamine modulation as the conventional treatment approach. The competitive landscape is undergoing dynamic changes with generic approvals for LATUDA and REXULTI, while current pharmacologic options continue to face challenges in addressing the full spectrum of the disorder, particularly negative and cognitive symptoms. Prominent players including Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, and Newron Pharmaceuticals are advancing candidates through late-phase clinical development, reflecting a concerted industry effort to address the complexities of schizophrenia through innovative and diverse therapeutic interventions.

Scope of the Schizophrenia Market Report

Study Period: 2022–2036

Forecast Period: 2026–2036

Market Size (2025): ~USD 8 Billion (7MM)

Geographies Covered: The US; EU4 (Germany, France, Italy, and Spain); UK; Japan

Major Schizophrenia Companies: Boehringer Ingelheim, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Karuna Therapeutics, Bristol Myers Squibb, Royalty Pharma, Acadia Pharmaceuticals, Rovi Pharmaceuticals Laboratories, Teva Pharmaceutical, MedinCell, Lyndra Therapeutics, Neurocrine Biosciences, Luye Pharma, Newron Pharmaceuticals, and others.

Market Segments Covered: Total Schizophrenia Market Size, Schizophrenia Market Size by Therapies, Schizophrenia Market Size by Class.

Epidemiology Segmentation: Total prevalent cases of Schizophrenia in the 7MM, total diagnosed cases of Schizophrenia in the 7MM, gender-specific cases of Schizophrenia in the 7MM, severity-specific cases of Schizophrenia in the 7MM, age-specific treated cases of Schizophrenia in the 7MM, total treated cases of Schizophrenia in the 7MM.

Key Focus Areas: Schizophrenia Drugs Analysis, Schizophrenia Marketed Drugs, Schizophrenia Emerging Drugs, Schizophrenia Drugs Uptake, and Schizophrenia Treatment Practices.

Table of Contents

1. Key Insights

2. Report Introduction

3. Schizophrenia Market Overview at a Glance

4. Methodology of Schizophrenia Epidemiology and Market

5. Executive Summary of Schizophrenia

6. Key Events

7. Disease Background and Overview

8. Patient Journey

9. Epidemiology and Patient Population

10. Marketed Drugs

11. Emerging Drugs

12. Schizophrenia: Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

How DelveInsight’s Schizophrenia Market Report Helps CXOs and Business Leaders

• Evaluate the current and future market opportunity across key regions, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, through detailed epidemiology forecasts and market size assessments.

• Benchmark leading Schizophrenia marketed and emerging drugs, including COBENFY, olanzapine LAI (TEV-‘749), and brilaroxazine, through comprehensive competitive intelligence and product profiling.

• Identify potential licensing, acquisition, co-development, and strategic partnership opportunities by monitoring emerging Schizophrenia Companies, novel mechanisms of action, and recent clinical trial developments.

• Assess the impact of upcoming regulatory approvals, generic entries for LATUDA and REXULTI, and product launches on market share, adoption rates, and commercial success.

• Support strategic decision-making with insights into key opinion leader (KOL) perspectives, unmet treatment needs, epidemiology segmentation, and evolving market dynamics within the Schizophrenia landscape.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Abhishek kumar
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/schizophrenia-market